Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

ABT brings in $15M investment for market advancement

Producers of cyclotron and PET generator technologies ABT Molecular Imaging announced Oct. 20 that the company would be expanding into global markets with a $15 million boost in financing.

Thumbnail

Stem cells engineered to fight brain cancer

Toxins produced by highly specialized stem cells work to treat brain cancer. Researchers from Harvard Medical School are the engineers behind these killer stem cells.

Thumbnail

PET/CT: Toshiba presents new large-bore system

Toshiba is bringing what is being called the industry’s largest-bore PET/CT to the upcoming Radiological Society of North America (RSNA) annual meeting next month in Chicago from Nov. 30-Dec. 5, according to an Oct. 27 announcement.

Thumbnail

Lilly to pay reduced punitive damages in bladder cancer trial

Eli Lilly and Company, makers of amyloid PET agent Amyvid, announced yesterday evening that the judge in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, has ruled to reduce punitive damages for defendants Takeda and Lilly from $6 billion and $3 billion, respectively, down to $27.6 million and $9.2 million.

Thumbnail

Hyperpolarized lung MRI portrays the perils of smoking

A relatively new MR technique that vastly improves imaging resolution is able to find the minute lung pathology associated with smoking habits—even before respiratory symptoms become a drag, according to a study published ahead of print Oct. 13 in Radiology.

Thumbnail

Navidea names Rick Gonzalez chief executive officer

Rick Gonzalez, former vice president of global operations for Spectrum Pharmaceuticals, is the new chief executive officer for Navidea Biopharmaceuticals, producers of Lymphoseek, the company announced recently.

Sofie saddles $1.5M SBIR grant for phase II PET probes

Sofie Biosciences, producers of PET imaging systems and agents, has been awarded a two-year $1.5 million phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute to further develop oncologic PET agents, the company recently announced.

NanoHybrids gets NIH grant for atherosclerotic plaque imaging

The National Institutes of Health (NIH) will be bankrolling a Small Business Innovation Research (SBIR) grant for Austin-based NanoHybrids to develop contrast agents for the detection of atherosclerotic plaques, the company announced today.